NuVasive (NUVA) : Traders are getting increasingly bearish on NuVasive (NUVA), as can be seen in the addition of short positions from 3,541,005 on Jul 29, 2016, to 3,702,837 on August 15, 2016. The net change in shorts is 161,832 shares, an increase of 4.6%. 10 days remain before the expiry. The 7.5% of outstanding short positions on the stock compared to its float, shows that traders expect the stock to fall from the current levels. The daily volume of the stock is 370,841. The short interest information was released on Wednesday Aug 24th after the market close.
NuVasive (NASDAQ:NUVA): The stock opened at $64.24 on Wednesday but the bulls could not build on the opening and the stock topped out at $64.60 for the day. The stock traded down to $62.71 during the day, due to lack of any buying support eventually closed down at $63.16 with a loss of -1.47% for the day. The stock had closed at $64.10 on the previous day. The total traded volume was 595,125 shares.
In a related news, The director, of Nuvasive Inc, Howe Lesley H had unloaded 3,602 shares at $62.44 per share in a transaction on August 2, 2016. The total value of transaction was $224,909. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Nuvasive, Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems, including NVM5 and NVJJB, Intra-Operative Monitoring (IOM) services and support; MaXcess, which is an integrated split-blade retractor system, and a variety of implants and biologics.